1. Search Result
Search Result
Results for "

Erlotinib

" in MCE Product Catalog:

11

Inhibitors & Agonists

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-50896
    Erlotinib

    CP-358774; NSC 718781; OSI-774

    EGFR Autophagy Cancer
    Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer.
  • HY-50896S
    Erlotinib-d6

    CP-358774-d6; NSC 718781-d6; OSI-774-d6

    EGFR Cancer
    Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR.
  • HY-12008S
    Erlotinib-d6 hydrochloride

    CP-358774-d6 hydrochloride; NSC 718781-d6 hydrochloride; OSI-774-d6 hydrochloride

    EGFR Autophagy Cancer
    Erlotinib D6 hydrochloride (CP-358774 D6 hydrochloride) a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-12008A
    Erlotinib mesylate

    CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate

    EGFR Autophagy Cancer
    Erlotinib mesylate (CP-358774 mesylate) inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-12008
    Erlotinib Hydrochloride

    CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride

    EGFR Autophagy Cancer
    Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-50896S1
    Erlotinib-13C6

    CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6

    EGFR Autophagy Cancer
    Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR.
  • HY-13256AS
    Desmethyl Erlotinib-d4

    Drug Metabolite Cancer
    Desmethyl Erlotinib-d4 (OSI-420-d4 free base) is the deuterium labeled Desmethyl Erlotinib. Desmethyl Erlotinib (OSI-420 free base) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor.
  • HY-13256
    Desmethyl Erlotinib hydrochloride

    OSI-420; CP-373420 hydrochloride

    Drug Metabolite Cancer
    Desmethyl Erlotinib hydrochloride (OSI-420) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor.
  • HY-13256A
    Desmethyl Erlotinib

    OSI-420 free base; CP-373420

    Drug Metabolite Cancer
    Desmethyl Erlotinib (OSI-420 free base) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor.
  • HY-135699
    TD52

    Apoptosis Phosphatase Akt Cancer
    TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity.
  • HY-135699A
    TD52 dihydrochloride

    Akt Phosphatase Apoptosis Cancer
    TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity.